In the prostate cancer TME, Tregs are often recruited in large numbers, where they inhibit the activity of CD8+ cytotoxic T-cells and other effector immune cells, thereby fostering an immunosuppressive environment that enables tumor cells to escape immune elimination. Here, CD8A is linked to prostate carcinoma.